Filtered By:
Drug: Activase

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Outcome after stroke thrombolysis in patients >80 years treated within 3 hours vs >3-4.5 hours
Conclusions: In this observational study, unselected patients >80 years of age treated with IVT after 3 hours vs earlier had a slightly higher rate of SICH and similar unadjusted functional outcome but poorer adjusted outcome. The absolute difference between the treatment groups is small, and elderly patients should not be denied IVT in the later time window solely because of age without other contraindications.
Source: Neurology - October 9, 2017 Category: Neurology Authors: Ahmed, N., Lees, K. R., Ringleb, P. A., Bladin, C., Collas, D., Toni, D., Ford, G. A., And the SITS Investigators Tags: All Cerebrovascular disease/Stroke ARTICLE Source Type: research

Factors influencing thrombectomy decision making for primary medium vessel occlusion stroke
Conclusions Most physicians in this survey were interventionalists and would treat patients with MeVO stroke immediately with EVT. This finding supports the need for robust clinical evidence.
Source: Journal of NeuroInterventional Surgery - March 18, 2022 Category: Neurosurgery Authors: Cimflova, P., Kappelhof, M., Singh, N., Kashani, N., Ospel, J. M., McDonough, R., Demchuk, A. M., Menon, B. K., Sakai, N., Chen, M., Fiehler, J., Goyal, M. Tags: Ischemic stroke Source Type: research

Thrombolysis for Acute Ischemic Stroke: Do Patients Treated Out of Hours Have a Worse Outcome?
Introduction: Previous studies on the impact of nonworking hours (NWH) have produced conflicting results. We aimed to compare the time to treatment with thrombolysis between NWH and working hours (WH) at an Australian comprehensive stroke center.Materials and Methods: All acute ischemic stroke patients treated with intravenous alteplase (IV-alteplase) from January 2003 to December 2011 at the Royal Melbourne Hospital were included. Data collected included demographics, serial time points (including onset, presentation to emergency department, neuroimaging, and thrombolysis), and clinical outcomes (modified Rankin Scale [mR...
Source: Journal of Stroke and Cerebrovascular Diseases - April 30, 2013 Category: Neurology Authors: Kun Fang, Leonid Churilov, Louise Weir, Qiang Dong, Stephen Davis, Bernard Yan Tags: Original Articles Source Type: research

Safety of Standard-dose (.9-mg/kg) Alteplase Intravenous Thrombolysis for Acute Ischemic Stroke in Afro–Caribbeans, French West Indies
Conclusions: The excess hemorrhagic risk after standard-dose alteplase infusion into older Afro–Caribbean patients warrants further study to determine the possible role of cerebral microangiopathy and should be evaluated in different black populations.
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Nicolas Chausson, Stéphane Olindo, Julien Joux, Martine Saint-Vil, Mathieu Aveillan, Didier Smadja Tags: Original Articles Source Type: research

Arterial Reocclusion And Distal Embolization During Endovascular Treatment Using New Generation Stent Retrievers In Acute Ischemic Stroke Patients (P4.299)
CONCLUSIONS: Arterial reocclusion and distal embolization occur in 16[percnt]-18[percnt] of acute ischemic stroke patients undergoing mechanical thrombectomy with new stent retrievers. The rates are no higher than those observed in cohorts treated without stent retrievers.Disclosure: Dr. Herial has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Jahangir has nothing to disclose. Dr. Zeb has nothing to disclose. Dr. Janjua has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Herial, N., Qureshi, M., Khan, A., Jahangir, N., Zeb, H., Janjua, N., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Interventional Treatment for Ischemic Stroke Source Type: research

Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke Basic Sciences
Conclusions— Our data demonstrate that DMT is an early phenomenon initiated before recanalization. We further show that alteplase-dependent maintenance of downstream perfusion during MCAO improves acute ischemic stroke outcome through a fibrinogen-dependent platelet aggregation reduction. Our results indicate that early targeting of DMT represents a therapeutic strategy to improve the benefit of large artery recanalization in acute ischemic stroke.
Source: Stroke - October 26, 2015 Category: Neurology Authors: Desilles, J.-P., Loyau, S., Syvannarath, V., Gonzalez-Valcarcel, J., Cantier, M., Louedec, L., Lapergue, B., Amarenco, P., Ajzenberg, N., Jandrot-Perrus, M., Michel, J.-B., Ho-Tin-Noe, B., Mazighi, M. Tags: Fibrinolysis, Fibrinogen/fibrin, Acute Cerebral Infarction, Brain Circulation and Metabolism, Thrombolysis Basic Sciences Source Type: research

Intra-Arterial Therapy and Post-Treatment Infarct Volumes: Insights From the ESCAPE Randomized Controlled Trial Clinical Sciences
Conclusions— These results support the primary results of the ESCAPE trial and show that the biological underpinning of the success of endovascular therapy is a reduction in infarct volume. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.
Source: Stroke - February 22, 2016 Category: Neurology Authors: Al-Ajlan, F. S., Goyal, M., Demchuk, A. M., Minhas, P., Sabiq, F., Assis, Z., Willinsky, R., Montanera, W. J., Rempel, J. L., Shuaib, A., Thornton, J., Williams, D., Roy, D., Poppe, A. Y., Jovin, T. G., Sapkota, B. L., Baxter, B. W., Krings, T., Silver, F Tags: Imaging, Quality and Outcomes, Ischemic Stroke Clinical Sciences Source Type: research

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy Clinical Sciences
Conclusions—Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.
Source: Stroke - June 26, 2017 Category: Neurology Authors: Thompson G. Robinson, Xia Wang, Hisatomi Arima, Philip M. Bath, Laurent Billot, Joseph P. Broderick, Andrew M. Demchuk, Geoffery A. Donnan, Jong S. Kim, Pablo M. Lavados, Tsong-Hai Lee, Richard I. Lindley, Sheila C. O. Martins, Veronica V. Olavarria, Jeya Tags: Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association AHA/ASA Scientific Statement
Purpose—Symptomatic intracranial hemorrhage (sICH) is the most feared complication of intravenous thrombolytic therapy in acute ischemic stroke. Treatment of sICH is based on expert opinion and small case series, with the efficacy of such treatments not well established. This document aims to provide an overview of sICH with a focus on pathophysiology and treatment.Methods—A literature review was performed for randomized trials, prospective and retrospective studies, opinion papers, case series, and case reports on the definitions, epidemiology, risk factors, pathophysiology, treatment, and outcome of sICH. The documen...
Source: Stroke - November 27, 2017 Category: Neurology Authors: Shadi Yaghi, Joshua Z. Willey, Brett Cucchiara, Joshua N. Goldstein, Nicole R. Gonzales, Pooja Khatri, Louis J. Kim, Stephan A. Mayer, Kevin N. Sheth, Lee H. Schwamm Tags: Statements and Guidelines AHA/ASA Scientific Statement Source Type: research

Reliability of the Acutely Estimated Premorbid Modified Rankin Scale for Stroke Treatment Decision Making
Background: Premorbid functional status is an important factor in acute stroke treatment decision making. Determining the modified Rankin Score (mRS) accurately may be difficult due to deficits from stroke and lack of collateral information in the acute setting. Data on the reliability of the premorbid mRS in “real-world” practice outside of clinical trial or registry settings are limited. Methods: A retrospective study at a high volume academic primary stroke center. For patients with acute ischemic stroke treated with alteplase between July 2012 and July 2016, hospital electronic records were revie wed for detailed i...
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2019 Category: Neurology Authors: WenWen Zhang, Skye Coote, Tanya Frost, Helen M. Dewey, Phillip M. Choi Source Type: research

Quality improvement project leads to better care of all stroke patients: Together we are stronger
Since the publication of the first IV thrombolysis trial with alteplase1 and subsequent analyses showing a strong correlation between early treatment and favorable outcome,2,3 the medical community has been focused on early identification of stroke and rapid delivery of suspected patients to the nearest alteplase-capable hospital. The importance of early stroke treatment created a need for a stroke system of care where there is a widespread network of medical facilities in which IV alteplase can be administered, and subsequent care can take place at another facility of higher level of care. The state of Minnesota has adopt...
Source: Neurology Clinical Practice - October 13, 2019 Category: Neurology Authors: Hussein, H. M., Ng, F. C. Tags: All Cerebrovascular disease/Stroke Editorial Source Type: research

Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study
This study was designed to evaluate the prestroke and baseline characteristics, stroke sub-types, complications, and outcomes of PCS patients and compare them with anterior circulation stroke (ACS) after intravenous thrombolysis. Methods: Data of consecutive patients with PCS and ACS treated with alteplase in a standard dose of 0.9 mg/kg in our stroke center were collected and analyzed retrospectively.
Source: Journal of Stroke and Cerebrovascular Diseases - December 1, 2019 Category: Neurology Authors: Xuan Zhu, Nuo Wang, Huangbin Lin, Ping Zhang, Lei Chen, Minmin Zhang, Benqiang Deng, Tao Wu Source Type: research

Prognostic Significance of Stroke-Associated Infection and other Readily Available Parameters in Acute Ischemic Stroke Treated by Intravenous Thrombolysis
The impact of contracting stroke-associate infection (SAI) that requires antibiotic treatment after an acute ischemic stroke (AIS) treated with alteplase remains unclear. We studied the profiles of SAI in patients with AIS treated with alteplase toward identifying predictive factors and prognostic implications at 90 days post-stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - December 15, 2020 Category: Neurology Authors: Justyna Derbisz, Klaudia Nowak, Marcin Wnuk, Roman Pulyk, Jeremiasz Jagiella, Joanna Slowik, Tomasz Dziedzic, Agnieszka Slowik Source Type: research

Influence of intravenous alteplase on endovascular treatment decision-making in acute ischemic stroke due to primary medium-vessel occlusion: a case-based survey study
Conclusions Intravenous alteplase is an important factor in EVT decision-making for MeVO stroke. However, even in alteplase-treated patients, more than half of the physicians decided to proceed with EVT without waiting for alteplase effect.
Source: Journal of NeuroInterventional Surgery - April 12, 2022 Category: Neurosurgery Authors: Kappelhof, M., Ospel, J., Kashani, N., Cimflova, P., Singh, N., Almekhlafi, M. A., Menon, B. K., Fiehler, J., Chen, M., Sakai, N., Goyal, M. Tags: Open access, Ischemic stroke Source Type: research